Stepwise radical endoscopic resection of the complete barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities

American Journal of Gastroenterology

Volumn 102, Issue 9, 2007, Pages 1853-1861

  Peters, Femke P ^a   Krishnadath, K K ^a   Rygiel, Agnieszka M ^a   Curvers, Wouter L ^a   Rosmolen, Wilda D ^a   Fockens, P ^a   Ten Kate, Fiebo J W ^b   Van Baal, Jantine W P M ^a   Bergman, Jacques J G H M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Departments of Pathology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P53;

ARTICLE; BARRETT ESOPHAGUS; CHROMOSOME 1; CHROMOSOME 9; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOSCOPIC SURGERY; ESOPHAGUS BIOPSY; GENE OVEREXPRESSION; GENETIC DISORDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SQUAMOUS EPITHELIUM;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 9; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PRECANCEROUS CONDITIONS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548139336     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01272.x     Document Type: Article

References (43)

1. May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: Acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002 14 : 1085 91.
2. Hage M, Siersema PD, Vissers KJ, et al. Genomic analysis of Barrett's esophagus after ablative therapy: Persistence of genetic alterations at tumor suppressor loci. Int J Cancer 2006 118 : 155 60.
3. Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000 119 : 624 30.
4. Hage M, Siersema PD, Vissers KJ, et al. Molecular evaluation of ablative therapy of Barrett's oesophagus. J Pathol 2005 205 : 57 64.
5. Giovannini M, Bories E, Pesenti C, et al. Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy 2004 36 : 782 7.
6. Seewald S, Akaraviputh T, Seitz U, et al. Circumferential EMR and complete removal of Barrett's epithelium: A new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003 57 : 854 9.
7. Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: A prospective study. Am J Gastroenterol 2006 101 : 1449 57.
8. Garewal H, Ramsey L, Sharma P, et al. Biomarker studies in reversed Barrett's esophagus. Am J Gastroenterol 1999 94 : 2829 33.
9. Krishnadath KK, Tilanus HW, Alers JC, et al. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry. Cytometry 1994 15 : 176 84.
10. Polkowski W, Meijer GA, Baak JP, et al. Reproducibility of p53 and Ki-67 immunoquantitation in Barrett's esophagus. Anal Quant Cytol Histol 1997 19 : 246 54.
11. Kusser WC, Levin DB, Glickman BW. Sensitive two-stage PCR of p53 genomic DNA exons 5-9. PCR Methods Appl 1993 2 : 250 2.
12. Neshat K, Sanchez CA, Galipeau PC, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994 106 : 1589 95.
13. Paulson TG, Galipeau PC, Reid BJ. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res 1999 9 : 482 91.
14. Sarbia M, Geddert H, Klump B, et al. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer 2004 111 : 224 8.
15. Barrett MT, Pritchard D, Palanca-Wessels C, et al. Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus. Cancer Res 2003 63 : 4211 7.
16. Doak SH, Jenkins GJ, Parry EM, et al. Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. Br J Cancer 2003 89 : 1729 35.
17. Persons DL, Croughan WS, Borelli KA, et al. Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet Cytogenet 1998 106 : 11 7.
18. Haggitt RC, Tryzelaar J, Ellis FH, et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 1978 70 : 1 5.
19. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994 25 : 982 93.
20. Haggitt RC. Pathology of Barrett's esophagus. J Gastrointest Surg 2000 4 : 117 8.
21. Tselepis C, Perry I, Jankowski J. Barrett's esophagus: Disregulation of cell cycling and intercellular adhesion in the metaplasia-dysplasia-carcinoma sequence. Digestion 2000 61 : 1 5.
22. Koppert LB, Wijnhoven BP, van Dekken H, et al. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005 92 : 169 90.
23. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996 13 : 1867 73.
24. Gonzalez MV, Artimez ML, Rodrigo L, et al. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 1997 50 : 212 7.
25. Klump B, Hsieh CJ, Holzmann K, et al. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998 115 : 1381 6.
26. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001 61 : 8284 9.
27. Gleeson CM, Sloan JM, McGuigan JA, et al. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 1995 55 : 3406 11.
28. Buttar NS, Wang KK, Lutzke LS, et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 2001 54 : 682 8.
29. Pacifico RJ, Wang KK, Wongkeesong LM, et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 2003 1 : 252 7.
30. Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. Gastrointest Endosc 2005 61 : 506 14.
31. Paulson TG, Xu L, Sanchez C, et al. Neosquamous epithelium does not typically arise from Barrett's epithelium. Clin Cancer Res 2006 12 : 1701 6.
32. Biddlestone LR, Barham CP, Wilkinson SP, et al. The histopathology of treated Barrett's esophagus: Squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998 22 : 239 45.
33. Long JD, Orlando RC. Esophageal submucosal glands: Structure and function. Am J Gastroenterol 1999 94 : 2818 24.
34. Peters FP, Curvers WL, Kara MA, et al. Stepwise radical endoscopic resection for complete removal of Barrett's esophagus with early neoplasia [abstract ]. Gastrointest Endosc 2006 63 : AB133.
35. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: Long-term results. Gastrointest Endosc 2003 58 : 183 8.
36. Peters F, Kara M, Rosmolen W, et al. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in Barrett esophagus after endoscopic resection. Endoscopy 2005 37 : 418 24.
37. Wang KK, Buttar NS, Wong Kee Song LM, et al. Assessment of genetic defects in patients with complete versus partial ablation after photodynamic therapy (PDT) for Barrett's esophagus [abstract ]. Gastroenterology 2004 126 : A-177.
38. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999 22 : 106 9.
39. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000 60 : 5021 6.
40. Galipeau PC, Prevo LJ, Sanchez CA, et al. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999 91 : 2087 95.
41. Maley CC, Galipeau PC, Li X, et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004 64 : 3414 27.
42. Maley CC, Reid BJ. Natural selection in neoplastic progression of Barrett's esophagus. Semin Cancer Biol 2005 15 : 474 83.
43. Prevo LJ, Sanchez CA, Galipeau PC, et al. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999 59 : 4784 7.